More than 70 children, on average, are diagnosed with cancer each year at CHKD. Anthem LemonAid is a fundraising campaign ...

HealthDay News — For women with breast cancer (BC), BRCA mutations are associated with increased risk of developing breast implant–associated anaplastic large cell lymphoma (BIA-ALCL), according to a ...

A real-world study showed a 49% response rate with Amtagvi in patients with advanced melanoma, supporting earlier use after immunotherapy.

Explore the latest advancements in immunotherapies for T-cell lymphoma, addressing unique challenges and promising new treatment options.

The FDA and the EMA have authorised AB Science’s confirmatory Phase III Study AB22007 trial of masitinib for mCRPC.

Cancer is not a welcome diagnosis, but breakthroughs in genetic sequencing and immunotherapy are making some cancers easier ...

ADX-2191 has received FDA Orphan Drug Designation for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. About Primary Vitreoretinal Lymphoma Primary vitreoretinal lymphoma is a ...

BIA-ALCL is a type of T-cell lymphoma that arises near textured breast implants, either as a collection of fluid or mass. It usually develops seven to 10 years after women undergo mastectomy and ...

Anaplastic large cell lymphoma (ALCL) belongs to the subgroup of non-Hodgkin's lymphomas and is a rare but aggressive form of T-cell lymphoma that usually occurs in children and young adults.

A lymph node biopsy confirmed anaplastic large cell lymphoma (ALCL), anaplastic lymphoma kinase (ALK)-negative, characterized by strong CD30 expression. Peripheral blood involvement in ALK-negative ...

ALCL often responds well to treatment, especially if the lymphoma cells have too much of the ALK protein. If the lymphoma returns after initial treatment, other chemo drugs (or other types of drugs) ...